Surufatinib with immunotherapy and chemo for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of surufatinib (a targeted drug) plus immunotherapy and chemotherapy for people with bile duct or gallbladder cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct or gallbladder cancer that has spread or cannot be removed by surgery.
- You are at least 18 years old.
- You are in fairly good health (able to care for yourself, up and around more than 50% of waking hours).
- Your liver and kidney function are good enough based on blood tests.
- You have not had other cancer treatments within 4 weeks before starting the study.
- You agree to use effective birth control during the study and for 6 months after the last dose if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (surufatinib), immunotherapy (serplulimab), and standard chemotherapy as a first treatment for advanced solid tumors that have neuroendocrine features. It aims to see if this combination can shrink tumors and improve outcomes for patients with certain cancers.
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (surufatinib and toripalimab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of treatments for people with bile duct or gallbladder cancer that cannot be removed by surgery. It uses a procedure to burn the tumor (radiofrequency ablation) along with two drugs: one that boosts your immune system and one that targets blood vessels feeding the cancer.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.